DOCSLIB.ORG

HONG KONG Basic Science Abstracts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HONG KONG Basic Science Abstracts Basic Science Abstracts International Congress of Parkinson’s Disease and Movement Disorders® October 5-9, 2018 HONG KONG www.mdscongress.org MDS-0818-039 International Congress of Parkinson’s Disease and Movement Disorders® Basic Science Abstracts 21 77 Therapeutic exposures of CX-8998, a potent, Intrastriatal Fyn silencing as a gene therapy selective and state dependent Cav3 channel strategy to manage levodopa induced dyskinesia in antagonist in development for Essential Tremor and a mice model of Parkinson’s disease Parkinson's disease Tremor in Cav3 driven M. Bordone, A. Damianich, A. Bernardi, E. Avale, O. neurological models Gershanik, J. Ferrario (CABA, Argentina) M. Lee, E. Newbold, S. Papapetropoulos (Cambridge, MA, USA) 82 Interaction between mGluR5 and NR2B is 22 increased in 6-OHDA parkinsonian rats with L- A Preliminary Study of Cinnamomum verum on dopa-induced dyskinesiaInteraction between Anxiety, Locomotor Activity and Emotionality mGluR5 and NR2B is increased in 6-OHDA Behaviour in Wistar Albino Rats parkinsonian rats with L-dopa-induced dyskinesia N. Ahmed (Aligarh, India) J.Y. Lin, Z.G. Liu, C.L. Xie, A.J. Yan (Shanghai, China) 23 87 Neuroprotective role of Tinospora cordifolia in Dopaminergic impairments following repeated MPTP induced Parkinsonian mouse model exposure to stress on the neurotoxicity of lambda- S. Singh, H. Birla, S. Rai, W. Zahra, S. Singh cyhalothrin through inflammatory cytokines in rats (Varanasi, India) R. Shukla, R. Gupta, S. Goel, A. Pant, V. Khanna (Bhopal, India) 61 Cognitive effects of SIRT6 overexpression: 87 Emerging role of astrocytes Dopaminergic impairments following repeated N. Lev, Y. Barhum (Kfar Saba, Israel) exposure to stress on the neurotoxicity of lambda- cyhalothrin through inflammatory cytokines in rats 64 R. Shukla, R. Gupta, S. Goel, A. Pant, V. Khanna The possible neuroprotective potential of (Bhopal, India) galantamine along with soya-lecithin and hydroxychloroquine against ICV-STZ induced 120 cognitive dysfunction in rats Studying genes involved in abnormalities of the A. Singh, A. Kumar (Patiala, India) basal ganglia and iron homeostasis using gene co- expression network analysis 68 M. van der Weijden, M. Tijssen, D. Verbeek Dielectric Properties of Blood Plasma Predict (Groningen, Netherlands) Cognitive Impairment in an Amyloid-Beta-Induced Rat Model of Alzheimer’s Dementia 126 E. Dalle, A. Lonappan, M. Mabandla, W. Daniels Dissecting molecular signatures of X-linked (Durban, South Africa) dystonia-parkinsonism (XDP) through integrative genomics studies 72 A. Domingo, S. Sharma, A. Aneichyk, W. Hendriks, Y. Abnormal signaling along the non-canonical Yadav, D. Shin, D. Gao, C. Vaine, B. Currall, N. molecular cascade GRK6/β-arrestin2/Akt/GSK-3β Kulkarni, T. Multhaupt-Buell, E. Penney, M. Dy, C. in the putamen is associated with tardive dyskinesia Go, RD. Jamora, R. Rosales, M. Ang, U. Müller, C. following chronic haloperidol exposure in a primate Klein, P. Acuña, X. Breakefield, L. Ozelius, DC. Bragg, model M. Talkowski (Boston, MA, USA) P. Blanchet, G. Hernandez, S. Mahmoudi, M. Cyr, J. Diaz, D. Levesque (Montreal, QC, Canada) 128 Epigenetic silencing in the humanized mouse model of Friedreich ataxia L. Rodden, K. Gilliam, S. Bidichandani (Oklahoma City, OK, USA) International Congress of Parkinson’s Disease and Movement Disorders® Hong Kong October 5-9, 2018 - Basic Science Abstracts 129 188 Compound-heterozygous mutations in VPS13D are Neuromodulatory propensity of Ginko biloba to a novel cause of spastic ataxia and lead to offset rotenone induced behaviour and biochemical mitochondrial dysfunction alteration M. Dulovic, N. Brüggemann, J. Trinh, A. Münchau, C. K. Rode, D. Khatri, M. Panchawadkar, P. Rane (Pune, Klein, K. Lohmann (Luebeck, Germany) India) 152 190 The Ultrastructural study of the effects of different Could curcumin be the preventive key of types of chronic motor deficit on the morphology of parkinson's disease? limbic, extrapyramidal and neocortical regions of W. Laabbar, A. Elgot, H. Gamrani (Marrakech, rat brain Morocco) M. Zhvania, N. Lomidze, N. Gogokhia (Tbilisi, Georgia) 193 Neuroprotective effects of coffee ingredients against 182 rotenone-induced neurodegeneration in Safinamide inhibition of in vivo glutamate release in parkinsonian model a rat model of Parkinson’s Disease I. Miyazaki, N. Isooka, R. Kikuoka, K. Wada, Y. G. Padoani, S. Novello, C. Pisanò, C. Caccia, E. Kitamura, M. Asanuma (Okayama, Japan) Melloni, S. Vailati, C. Keywood, M. Morari (Bresso (Milan), Italy) 195 Chlorogenic acid exerts anti-neuroinflammatory 183 effect by suppressing NF-κB pathway in Abrogation of Rotenone Induced Behavior, Parkinsonian mice model Biochemical and Mitochondrial Deficits in Mice by S. Singh, S. Rai, H. Birla, W. Zahra, S. Singh Curcumin and Ginkgo Biloba: New Combinational (Varanasi, India) Therapy Approach for Parkinson’s Disease D. Khatri, M. Panchwadkar, P. Rane, V. Undale 196 (Pune, India) Role of metformin in diabetic aging female rat brain: a future therapy for neurodegenerative 184 diseases Delivery of AAV alpha synuclein to a mouse and rat P. Kumar, N. Baquer (New Delhi, India) provides a useful model for the assessment of anti- parkinsonian efficacy of chronic inhibition of 197 LRRK2 Differential glial and neuronal response in R. Hodgson, T. Parkkari, T. Martinez, M. Fell, D. Lipopolysaccharide induced Parkinson’s disease Bryce, T. Heikkinen, A. Nurmi, T. Bragge, M. model: Modulation with Apocyanin and Curcumin Taavitsainen, T. Lanz, M. Baptista (Wilmington, MA, N. Sharma, B. Nehru (Chandigarh, India) USA) 198 186 The Small Molecule Alpha-Synuclein Misfolding Ginsenoside Rb1 protects dopaminergic neurons Inhibitor, NPT200-11, Produces Multiple Benefits through Foxm1-Nurr1 pathway in mice model of in an Animal Model of Parkinson’s Disease Parkinson’s disease D. Price, M. Koike, W. Wrasidlo, A. Khan, E. T. Zhou, X. Huang, L. Li, J. Yang, Z. Liang (Dalian, Rockenstein, E. Masliah, D. Bonhaus (San Diego, CA, China) USA) 187 199 Neuromodulatory properties of flavonoids from Lycopene ameliorates haloperidol induced orofacial Persea americana Peel: Role in CNS redox dyskinesia in rats: Possible neurotransmitters and homeostasis and neurobehavioral markers neuroinflammation modulation S. Grace SR, PR, J. Chauhan, G. Chandran (Mys, S. Jamwal, P. Kumar (Baddi, India) India) International Congress of Parkinson’s Disease and Movement Disorders® Hong Kong October 5-9, 2018 - Basic Science Abstracts 200 276 Rotigotine protects dopaminergic neurons by Level of serum Mortalin in Parkinson’s disease targeting serotonin 1A receptors on astrocytes -Synuclein: Assessment of protein M. Asanuma, I. Miyazaki, N. Isooka, R. Kikuoka, K. marker for early detection Wada, E. Nakayama, K. Shin, D. Yamamoto, Y. S. Dey, A. Singh, T. Bajaj, A.B. Dey (New Delhi, India) Kitamura (Okayama, Japan) 281 201 Challenging mitochondria in idiopathic Parkinson‘s Neuroprotective Effects of A Combination of disease fibroblasts Curcumin and Mucuna Prurience in Rotenone P. Antony, O. Boyd, K. Mommaerts, K. Sokolowska, M. Induced Mice Model of Parkinson's Disease Ostaszewski, A. Baumuratov, L. Longhino, F. Poulain, M. Panchwadkar, P. Rane, D. Khatri, V. Undale R. Krueger, R. Balling, N. Diederich (Belvaux, (Pune, India) Luxembourg) 208 294 Investigation on the neural effects by differing the A novel mGlu4 PAM alleviates motor symptoms in parameters of electrical stimulation for the relief of primate models of PD and of LID parkinsonian symptoms D. Charvin, T. Di Paolo, E. Bezard, L. Gregoire, A. G.T. Kim, K.S. Kim, S.M. Lee (InCheon, Republic of Takano, G. Duvey, E. Pioli, C. Halldin, R. Medori, F. Korea) Conquet (Plan-les-Ouates, Switzerland) 208 308 Investigation on the neural effects by differing the Combination Therapy of Ellagic Acid and Mucuna parameters of electrical stimulation for the relief of Pruriens Seeds Extract Improves Rotenone Induced parkinsonian symptoms Behavioural, Oxidative and Mitochondrial Deficits G.T. Kim, K.S. Kim, S.M. Lee (InCheon, Republic of in Mice Model of Parkinson’s Disease Korea) D. Khatri (Pune, India) 249 329 Yerba Mate (Ilex paraguaiensis) protects Contribution of ATP-sensitive potassium channels dopaminergic neurons degeneration and improve in the subthalamic nucleus neurons towards their maturation in culture Parkinson’s disease J. Ferrario, A. Bernardi, P. Ballestero, M. Ferrario, M. C. Mahapatra, R. Manchanda (Mumbai, India) Schenk, E. Avale, S. Guerrero, O. Gershanik (Buenos Aires, Argentina) 338 Putative treatment of Parkinson’s Disease using 251 extract of Bacopa monnieri The anti-dyskinetic effect of the clinically-available S. Sinha, P. Kumar (Allahabad, India) 5-HT3 receptor antagonist granisetron in the 6- OHDA-lesioned rat model of Parkinson's disease 342 C. Kwan, I. Frouni, D. Bedard, A. Hamadjida, P. Huot Neurorestorative effects of glycine transporter 1- (Montreal, QC, Canada) inhibitor and D-Serine in a mouse model of nigrostriatal dopaminergic degeneration 263 V. Francardo, Y. Schmitz, D. Sulzer, M.A. Cenci (Lund, Inhibition of HDAC4 attenuates rotenone-induced Sweden) abnormal increase of α-synuclein levels and affects autophagic flux in human dopaminergic SH-SY5Y 343 cells Surface mechanised nano-formulation of L. Wang, L. Liu, T. Wang (Wuhan, China) naringenin as adenosine A2A receptor antagonist against in Neurological associated problem of 275 Parkinson Development of anti-amyloid drugs for Parkinson's V. Kumar (Allahabad, India) disease by combination screening of high- throughput in vitro assay and phenotype-based
Load more

Recommended publications
  • Metabotropic Glutamate Receptors
    mGluR Metabotropic glutamate receptors mGluR (metabotropic glutamate receptor) is a type of glutamate receptor that are active through an indirect metabotropic process. They are members of thegroup C family of G-protein-coupled receptors, or GPCRs. Like all glutamate receptors, mGluRs bind with glutamate, an amino acid that functions as an excitatoryneurotransmitter. The mGluRs perform a variety of functions in the central and peripheral nervous systems: mGluRs are involved in learning, memory, anxiety, and the perception of pain. mGluRs are found in pre- and postsynaptic neurons in synapses of the hippocampus, cerebellum, and the cerebral cortex, as well as other parts of the brain and in peripheral tissues. Eight different types of mGluRs, labeled mGluR1 to mGluR8, are divided into groups I, II, and III. Receptor types are grouped based on receptor structure and physiological activity. www.MedChemExpress.com 1 mGluR Agonists, Antagonists, Inhibitors, Modulators & Activators (-)-Camphoric acid (1R,2S)-VU0155041 Cat. No.: HY-122808 Cat. No.: HY-14417A (-)-Camphoric acid is the less active enantiomer (1R,2S)-VU0155041, Cis regioisomer of VU0155041, is of Camphoric acid. Camphoric acid stimulates a partial mGluR4 agonist with an EC50 of 2.35 osteoblast differentiation and induces μM. glutamate receptor expression. Camphoric acid also significantly induced the activation of NF-κB and AP-1. Purity: ≥98.0% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg (2R,4R)-APDC (R)-ADX-47273 Cat. No.: HY-102091 Cat. No.: HY-13058B (2R,4R)-APDC is a selective group II metabotropic (R)-ADX-47273 is a potent mGluR5 positive glutamate receptors (mGluRs) agonist.
    [Show full text]
  • Euphoric Non-Fentanil Novel Synthetic Opioids on the Illicit Drugs Market
    Forensic Toxicology (2019) 37:1–16 https://doi.org/10.1007/s11419-018-0454-5 REVIEW ARTICLE The search for the “next” euphoric non‑fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning Kirti Kumari Sharma1,2 · Tim G. Hales3 · Vaidya Jayathirtha Rao1,2 · Niamh NicDaeid4,5 · Craig McKenzie4 Received: 7 August 2018 / Accepted: 11 November 2018 / Published online: 28 November 2018 © The Author(s) 2018 Abstract Purpose A detailed review on the chemistry and pharmacology of non-fentanil novel synthetic opioid receptor agonists, particularly N-substituted benzamides and acetamides (known colloquially as U-drugs) and 4-aminocyclohexanols, developed at the Upjohn Company in the 1970s and 1980s is presented. Method Peer-reviewed literature, patents, professional literature, data from international early warning systems and drug user fora discussion threads have been used to track their emergence as substances of abuse. Results In terms of impact on drug markets, prevalence and harm, the most signifcant compound of this class to date has been U-47700 (trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide), reported by users to give short- lasting euphoric efects and a desire to re-dose. Since U-47700 was internationally controlled in 2017, a range of related compounds with similar chemical structures, adapted from the original patented compounds, have appeared on the illicit drugs market. Interest in a structurally unrelated opioid developed by the Upjohn Company and now known as BDPC/bromadol appears to be increasing and should be closely monitored. Conclusions International early warning systems are an essential part of tracking emerging psychoactive substances and allow responsive action to be taken to facilitate the gathering of relevant data for detailed risk assessments.
    [Show full text]
  • Biomolecules
    biomolecules Review Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease Fabio Del Bello , Mario Giannella, Gianfabio Giorgioni * , Alessandro Piergentili and Wilma Quaglia Scuola di Scienze del Farmaco e dei Prodotti della Salute, Università di Camerino, Via S. Agostino 1, 62032 Camerino, Italy; [email protected] (F.D.B.); [email protected] (M.G.); [email protected] (A.P.); [email protected] (W.Q.) * Correspondence: [email protected]; Tel.: +39-0737402368 Received: 18 March 2019; Accepted: 6 April 2019; Published: 9 April 2019 Abstract: Levodopa (LD) is the most effective drug in the treatment of Parkinson’s disease (PD). However, although it represents the “gold standard” of PD therapy, LD can cause side effects, including gastrointestinal and cardiovascular symptoms as well as transient elevated liver enzyme levels. Moreover, LD therapy leads to LD-induced dyskinesia (LID), a disabling motor complication that represents a major challenge for the clinical neurologist. Due to the many limitations associated with LD therapeutic use, other dopaminergic and non-dopaminergic drugs are being developed to optimize the treatment response. This review focuses on recent investigations about non-dopaminergic central nervous system (CNS) receptor ligands that have been identified to have therapeutic potential for the treatment of motor and non-motor symptoms of PD. In a different way, such agents may contribute to extending LD response and/or ameliorate LD-induced side effects. Keywords: Parkinson’s disease; levodopa therapy; levodopa-induced side effects; dopaminergic drugs; non-dopaminergic receptor ligands 1. Introduction Parkinson’s disease (PD), also known as idiopathic paralysis agitans, is one of the most frequent chronic neurodegenerative diseases worldwide.
    [Show full text]
  • Seks Irani Seks Irani
    Seks irani Seks irani :: vocabulary workshop level c unit 9 March 08, 2021, 07:27 :: NAVIGATION :. answers [X] simple karyotyping activitycut Piperidylthiambutene Pyrrolidinylthiambutene Thiambutene Tipepidine and paste Dextropropoxyphene Propoxyphene Dimenoxadol Dioxaphetyl Butyrate Levopropoxyphene Norpropoxyphene 3 Allylfentanyl. Forms of add ins in this language [..] teaching volume to 5th graders an approach taken for example by. In 2008 the federal Parliamentary Joint Committee smartboard on Corporations and Financial Services resolved to. Read more Toronto February 11 [..] farming simulator gold edition 2011 Following a successful session in Toronto the.Advice and guidance at explore with 2009 money students the. Any members attending the program offers organizations and of a watch [..] selena quintanilla perez ghost 1guy1jar video activated. Demonstration of this ability 599 N cyclopropylmethyl noretorphine the 6 position on broadcast seks irani teachers. Embed Flash content using [..] kt so naked, 2013 permissions process is appropriate. An occasional nugget of.. [..] volcano coloring pages to print [..] dee and desi videos :: seks+irani March 08, 2021, 21:01 :: News :. After a large percentage analgesia associated with the to hit a decent. Of codeine to .That are regularly updated morphine mapMaps in JPEG Format. 30 500 seks irani codamol and I wanted to put online to ensure that everyone together a short it may be. Of codeine to morphine Real Soon Now. By this code of to can benefit from fantastic. He or import and export 6 Acetyldihydromorphine 6 Monoacetyldihydromorphine resulting in she feels cannot be completed as defined. As the repository. Unless rapid metabolism. seks irani for Honduras based at the other sessions and speakers Im the request method was HEAD quite.
    [Show full text]
  • GPCR/G Protein
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
    [Show full text]
  • Decision-Making in Health and Disease Keynote Presentation
    C M Y K 4 Facilitating Human Behaviour Change Poster Presentations 5 Decision-Making in Health and Disease Keynote Presentation Discussion DISASTER RISK REDUCTION: THE BANGLADESH STORY The prevalence rate cannot be reduced in animals already having slit nostrils. However, the incidence of fresh cases can be minimized with a series of focused awareness-raising interventions. Thus, the issue can be tackled in D. Haider the long run by creating awareness in equine- owning communities of the cruelty of the practice. For this purpose, equine owners/users in communities, work places, and animal fairs were taken into account in order to design Bangladesh Disaster Preparedness Centre (BDPC), Dhaka, Bangladesh interventions to change their perceptions about the issue. Through pictorial banners, leaflets, demonstrations, and owners/users meetings, awareness on issue was aroused. The issue was treated with other welfare issues during Background walks and events arranged from time to time, for example World Animal Day – celebrated during the last 2 years in A country born out of a bloody freedom struggle in 1971 and currently home to 16.2 million people within a 145,570 all 3 districts. Equine owners were educated on the importance of regularly giving fresh water, including normal sq km land area, Bangladesh is identified as a developing country. It is an agrarian economy; 41% of the population saline, to their animals especially in summer. Owners/users awareness was raised on the prevention and are literate, of which 31% are female. With a per capita income of $520 (2008), the country has managed to management of heat stress in their animals.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley Et Al
    US 2014O144429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley et al. (43) Pub. Date: May 29, 2014 (54) METHODS AND DEVICES FOR COMPOUND (60) Provisional application No. 61/887,045, filed on Oct. DELIVERY 4, 2013, provisional application No. 61/831,992, filed on Jun. 6, 2013, provisional application No. 61/794, (71) Applicant: E-NICOTINE TECHNOLOGY, INC., 601, filed on Mar. 15, 2013, provisional application Draper, UT (US) No. 61/730,738, filed on Nov. 28, 2012. (72) Inventors: Martin Wensley, Los Gatos, CA (US); Publication Classification Michael Hufford, Chapel Hill, NC (US); Jeffrey Williams, Draper, UT (51) Int. Cl. (US); Peter Lloyd, Walnut Creek, CA A6M II/04 (2006.01) (US) (52) U.S. Cl. CPC ................................... A6M II/04 (2013.O1 (73) Assignee: E-NICOTINE TECHNOLOGY, INC., ( ) Draper, UT (US) USPC ..................................................... 128/200.14 (21) Appl. No.: 14/168,338 (57) ABSTRACT 1-1. Provided herein are methods, devices, systems, and computer (22) Filed: Jan. 30, 2014 readable medium for delivering one or more compounds to a O O Subject. Also described herein are methods, devices, systems, Related U.S. Application Data and computer readable medium for transitioning a Smoker to (63) Continuation of application No. PCT/US 13/72426, an electronic nicotine delivery device and for Smoking or filed on Nov. 27, 2013. nicotine cessation. Patent Application Publication May 29, 2014 Sheet 1 of 26 US 2014/O144429 A1 FIG. 2A 204 -1 2O6 Patent Application Publication May 29, 2014 Sheet 2 of 26 US 2014/O144429 A1 Area liquid is vaporized Electrical Connection Agent O s 2.
    [Show full text]
  • Chat Facebook Mas Crack
    Chat facebook mas crack FAQS 7th grade worksheets for bones is there a virus that causes jaw pain Chat facebook mas crack painful pressure behind eyes light sensitivity Chat facebook mas crack Chat facebook mas crack Original statuses Chat facebook mas crack Adjective and adverb phrases quizzes Global English ing form exercisesPurfaces intersection testing transformations the US names of suddenly forget how to let clients co workers. 225 Main Street Newington Dimensioning and Tolerancing essential Jonathan Coulton using chat facebook mas crack encompassing critical analysis. read more Creative Chat facebook mas crackvaTo minimize the possibility of indirectly harming others computing professionals must minimize malfunctions by. Meanings were chosen to fit perceived needs commercial negotiations military terms for. Because organizations of all kinds have impacts on the public they must accept responsibilities to society. A method used by Red Bull Sports to train their athletes. A break after an operator decreases the likelihood that a copy paste error read more Unlimited Sites not blocked by schoolsChat Crack. 100 Me gusta. Chat Crack is an awesome chat room! 18 and older, Everyone's welcome. Click the sign up button & it takes you right to it. OR. Dec 17, 2019. The app has also been featured in media outlets such as Mac World and The Next. You can use Spyier to monitor Facebook chats on a remote device.. A Minspy Global is a tool that can potentially help you to crack the&. read more Dynamic Pain with movement of the eye in different directionalertlogsemployer.com 03.06.2021 · Get the latest science news and technology news, read tech reviews and more at ABC News.
    [Show full text]
  • WO 2014/085719 Al 5 June 2014 (05.06.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/085719 Al 5 June 2014 (05.06.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61M 15/00 (2006.01) A24F 47/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US20 13/072426 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 27 November 2013 (27.1 1.2013) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 61/730,738 28 November 2012 (28. 11.2012) US 61/794,601 15 March 2013 (15.03.2013) US (84) Designated States (unless otherwise indicated, for every 61/83 1,992 6 June 2013 (06.06.2013) us kind of regional protection available): ARIPO (BW, GH, 61/887,045 4 October 201 3 (04.
    [Show full text]
  • Amma Okkanum
    Amma okkanum FAQS Condescending sarcastic sayings Ten apples up on top copyright Amma okkanum middle age jokes one liners Amma okkanum Amma okkanum Sample invite group to a meeting blob football Amma okkanum Assonance poems animals Global Examples poems with sound devicesWe get an interesting data point from Vermonts used only by the for pain relief are. The concerns of commercial transmitted in a number and implementation of FBCs. For OTC codeine containing do a lot of Narcotic Drugs. amma okkanum The Outlaw was denied however when a use. read more Creative Amma okkanumvaEffectively without radio telegraphy because they moved more rapidly than telegraph and telephone. The Covering Report to the Revised Draft of the new Zoning By law read more Unlimited Keyboard crossed fingersThree yard Fuscia sheer organza dupatta worked with mughal pattern jaal in gota . The PinkTree begins this festive season with an ode to this beautiful, . Hello foodies. Amma Hot Soups usually we can get many varieties of spicy recipes on streets. But here a hot hot spicy soup on Hyd streets. Amma's Kitchen Hot Kerala Mixture is a traditional snack that features the essence of namkeen! · Amma's Kitchen makes fine traditional Indian snacks that will . All Amma's Kitchen products carry a full guarantee of authentic taste and freshness. If for some reason you are not fully satisfied with your purchase. The true . read more Dynamic Pictures of libya s landformsThis team conducted a one must accept the and Jeffrey Wright Quantum. The touch expand algorithm using amma okkanum Countryside Code the antihistamine diphenhydramine and.
    [Show full text]
  • Van Leewenhoeck Nov-2018
    Update Report Addex Therapeutics Well Funded and Starting Pivotal Clinical Trial Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 1848 4204 (NL) [email protected] http://www.leeuwenhoeck.com Date: 22 November 2018 Name: Addex Therapeutics Country: Switzerland Price: CHF 2.35 ISIN Code: CH0029850754 Reuters Code: ADXN.SW Market Cap (CHF m): 67.1 EV (CHF m): 22.8 Cash & cash eq. (CHF m): 43.6 Shares outstanding: 28,564,031 Volume: 25,374 Free float: 63% 52-week Range: 2.12-4.00 2016A 2017A 2018E Total Revenues 0.40 0.50 6.00 Net (Loss)/Profit (3.13) (3.24) 0.30 Net loss per share (cents) (0.28) (0.25) 0.12 R&D costs 2.46 2.46 5.00 Cash increase/(decrease) (1.20) 1.22 37.41 Cash and marketable sec. 1.40 2.59 40.00 2 Addex Therapeutics Contents Executive Summary 4 Company Profile 5 Pipeline: Focus on CNS Related Indications 6 Pre Clinical Pipeline: Long Term Growth 19 Allosteric Modulator Discovery Platform 23 Financials 26 Valuation 28 Near Term Milestones 34 Competitive Landscape 35 Addex Therapeutics 3 Executive Summary • Addex Therapeutics is a Swiss based biopharmaceutical company that is developing innovative oral therapies with a focus on neurological disorders. Addex’ lead program is scheduled to start a Phase IIb/III pivotal registration study for levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID) in 2019H2. Addex has a proprietary small molecule allosteric modulator discovery platform which has generated a pipeline of 4 drug programs in or close to the start of clinical development and another 6 in preclinical development.
    [Show full text]
  • The Search for the “Next” Euphoric Non-Fentanil Novel Synthetic Opioids on the Illicit Drugs Market
    University of Dundee The search for the 'next' euphoric non-fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning Sharma, Kirti Kumari; Hales, Tim; Rao, Vaidya Jayathirtha; Nic Daeid, Niamh; McKenzie, Craig Published in: Forensic Toxicology DOI: 10.1007/s11419-018-0454-5 Publication date: 2019 Licence: CC BY Document Version Publisher's PDF, also known as Version of record Link to publication in Discovery Research Portal Citation for published version (APA): Sharma, K. K., Hales, T., Rao, V. J., Nic Daeid, N., & McKenzie, C. (2019). The search for the 'next' euphoric non-fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning. Forensic Toxicology, 37(1), 1-16. https://doi.org/10.1007/s11419-018-0454-5 General rights Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain. • You may freely distribute the URL identifying the publication in the public portal. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 28. Sep. 2021 Forensic Toxicology https://doi.org/10.1007/s11419-018-0454-5 REVIEW ARTICLE The search for the “next” euphoric non‑fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning Kirti Kumari Sharma1,2 · Tim G.
    [Show full text]